Drugs that contain Paliperidone Palmitate

1. List of Invega Hafyera drug patents

INVEGA HAFYERA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(13 years from now)

US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by ad...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's patent expiration?
More Information on Dosage

INVEGA HAFYERA family patents

4

United States

3

Australia

3

Japan

2

Morocco

2

Canada

2

European Union

1

Denmark

1

Hong Kong

1

Slovenia

1

Lithuania

1

Hungary

1

Moldova, Republic of

1

Croatia

1

Brazil

1

Portugal

1

Spain

1

Korea, Republic of

1

Poland

1

Taiwan, Province of China

1

RS

1

Ukraine

EA

1

EA

1

New Zealand

2. List of Invega Sustenna drug patents

INVEGA SUSTENNA's oppositions filed in EPO
INVEGA SUSTENNA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(7 years from now)

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's patent expiration?
More Information on Dosage

INVEGA SUSTENNA family patents

5

United States

3

Korea, Republic of

3

European Union

2

Australia

2

China

1

Israel

1

Denmark

1

Hong Kong

1

Slovenia

1

Lithuania

1

Hungary

1

Colombia

1

Croatia

1

Brazil

1

Portugal

1

Guatemala

1

Spain

1

Poland

1

RS

1

Ecuador

1

Nicaragua

1

Ukraine

1

Japan

EA

1

EA

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic